期刊
REGENERATIVE THERAPY
卷 11, 期 -, 页码 95-100出版社
ELSEVIER
DOI: 10.1016/j.reth.2019.06.004
关键词
Regeneration; Pluripotent stem cells; Direct reprogramming; Fibroblasts; Cardiomyocytes
资金
- JSPS, Japan [16K19426, 18K08114]
- Japan Heart Foundation Research Grant, Japan
- Nakatomi Foundation, Japan
- Miyata Cardiac Research Promotion Foundation, Japan
- Grants-in-Aid for Scientific Research [16K19426, 18K08114] Funding Source: KAKEN
Cardiovascular disease is the leading cause of death globally. Cardiomyocytes (CMs) have poor regenerative capacity, and pharmacological therapies have limited efficacy in severe heart failure. Currently, there are several promising strategies for cardiac regeneration. The most promising approach to remuscularize failing hearts is cell transplantation therapy using newly generated CMs from exogenous sources, such as pluripotent stem cells. Alternatively, approaches to generate new CMs from endogenous cell sources in situ may also repair the injured heart and improve cardiac function. Direct cardiac reprogramming has emerged as a novel therapeutic approach to regenerate injured hearts by directly converting endogenous cardiac fibroblasts into CM-like cells. Through cell transplantation and direct cardiac reprogramming, new CMs can be generated and scar tissue reduced to improve cardiac function; therefore, cardiac regeneration may serve as a powerful strategy for treatment of severe heart failure. While substantial progress has been made in these two strategies for cardiac regeneration over the past several years, challenges remain for clinical translation. This review provide an overview of previous reports and current challenges in this field. (C) 2019, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据